Welcome to our dedicated page for Quidel news (Ticker: QDEL), a resource for investors and traders seeking the latest updates and insights on Quidel stock.
QuidelOrtho Corporation (NASDAQ: QDEL) is a global leader in diagnostic healthcare solutions, specializing in rapid testing technologies that inform critical clinical decisions. This news hub provides investors and healthcare professionals with timely updates on the company's innovations, regulatory milestones, and market developments.
Access official press releases and curated analysis covering financial results, product launches, strategic partnerships, and advancements in immunoassay or molecular diagnostic technologies. Our repository simplifies tracking of QDEL's contributions to transfusion safety, infectious disease detection, and clinical chemistry solutions across 100+ countries.
Bookmark this page for direct access to essential updates about FDA clearances, international expansion efforts, and research breakthroughs. All content is sourced from verified channels to ensure accuracy in reporting on this NASDAQ-listed innovator's role in shaping diagnostic medicine.
QuidelOrtho (Nasdaq: QDEL), a leader in in vitro diagnostic technologies, announced its management team's participation in the 44th Annual William Blair Growth Stock Conference. The event is scheduled for June 5, 2024, in Chicago, IL. The company's presentation will take place at 1:20 p.m. CT. Interested parties can access the live webcast and replay on QuidelOrtho's Investor Relations page.
QuidelOrtho (Nasdaq: QDEL) has launched a new state-of-the-art distribution center in Pedricktown, New Jersey, enhancing its U.S. distribution footprint. This strategic move aims to strengthen supply chain resilience and improve the customer experience. Partnering with a third-party logistics provider, QuidelOrtho aims to fulfill orders more efficiently. The company is also committed to sustainability, introducing greener, paper-based packaging that is recyclable. This initiative is expected to impact 15-20% of its domestic shipments over the coming months.
QuidelOrtho reported global year-over-year revenue growth of 5% as reported and 6% in constant currency, excluding COVID-19 revenue. They are undergoing cost reduction initiatives to save approximately $100 million annually. The company suspended its 2024 financial guidance as they assess the business under a new President and CEO. Revenue for Q1 2024 was $711 million, with non-respiratory revenue flat at $574 million and respiratory revenue at $137 million, a 48% decrease due to lower COVID-19 revenue. The company appointed Brian J. Blaser as President and CEO effective May 6, 2024.
QuidelOrtho (Nasdaq: QDEL) appoints Brian J. Blaser as President and Chief Executive Officer, bringing over two decades of leadership experience in the In-Vitro Diagnostics Industry. The Board of Directors expands to eleven members, with Mr. Blaser joining on May 15, 2024. Known for his success in transformational strategies to drive revenue growth and profitability, Mr. Blaser's appointment is set to guide QuidelOrtho through its next phase of growth.
FAQ
What is the current stock price of Quidel (QDEL)?
What is the market cap of Quidel (QDEL)?
